This study looks at how a drug called resmetirom affects people with a liver disease known as non-alcoholic steatohepatitis (NASH) cirrhosis. NASH cirrhosis is a condition where the liver is damaged due to fat buildup. The study is double-blind, meaning neither the doctors nor the participants know who gets the actual drug or a placebo (a fake pill with no medicine). Participants will take an 80 mg pill of resmetirom or placebo every morning for about 3 years. The main goal is to see how long it takes for patients to have a liver-related event, like needing a liver transplant or experiencing certain liver problems. Before starting, there's a screening period of up to 60 days. The study is for people with well-compensated NASH cirrhosis, meaning their liver is still working well. However, people with other liver diseases or severe liver damage aren't eligible.

• Study duration is approximately 3 years with up to 60 days for screening.
• Participants take a pill every morning and won't know if it's the real drug or placebo.
• Key focus is on liver-related health events during the study period.